source
- Eli Lilly inks up to $5.9 billion partnership with Stipple Bio to develop cancer therapiesEli Lilly announced a new collaboration with Cambridge-based biotech Stipple Bio, valued at up to $5.9 billion, aimed at creating novel cancer medicines. The agreement gives Lilly access to Stippl…
- FDA rejects ivonescimab for lung cancer; J&J to acquire Ollin Biosciences for up to $3.3B, Senate votes on FDA commissionerThe FDA has denied the application for ivonescimab as a treatment for lung cancer, halting its development for that indication. Johnson & Johnson announced a deal to purchase Ollin Biosciences, a…